UK markets close in 1 hour 4 minutes
  • FTSE 100

    7,037.77
    +4.92 (+0.07%)
     
  • FTSE 250

    22,345.14
    +131.00 (+0.59%)
     
  • AIM

    1,239.03
    +4.94 (+0.40%)
     
  • GBP/EUR

    1.1623
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.4194
    +0.0056 (+0.40%)
     
  • BTC-GBP

    30,593.70
    -677.61 (-2.17%)
     
  • CMC Crypto 200

    1,207.69
    -45.46 (-3.63%)
     
  • S&P 500

    4,163.98
    +0.69 (+0.02%)
     
  • DOW

    34,276.18
    -51.61 (-0.15%)
     
  • CRUDE OIL

    65.84
    -0.43 (-0.65%)
     
  • GOLD FUTURES

    1,864.30
    -3.30 (-0.18%)
     
  • NIKKEI 225

    28,406.84
    +582.01 (+2.09%)
     
  • HANG SENG

    28,593.81
    +399.72 (+1.42%)
     
  • DAX

    15,362.66
    -33.96 (-0.22%)
     
  • CAC 40

    6,348.67
    -18.68 (-0.29%)
     

European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines

·1-min read

MADRID (Reuters) - Spain's Pharma Mar said on Thursday that the European Society of Medical Oncology (ESMO) had included the company's Lurbinectedin drug as a treatment option for a rare type of lung cancer in its clinical practice guidelines.

ESMO provides clinical guidelines for the treatment of a broad range of cancers based on consensus opinions of practitioners.

The group's updated guidance now endorses Lurbinectedin for patients who are undergoing or who have just finished a first round of platinum-based chemotherapy to treat small-cell lung cancer, Pharma Mar said.

Shares in the Madrid-based company were trading 2.1% higher at 95.96 euros ($114.92) per share after the announcement.

As small-cell lung cancer affects just 1.4 people per 100,000 people in the European Union, Lurbinectedin was granted orphan-drug designation for the treatment of rare diseases by the European Medicines Agency in 2019.

It was approved as a treatment of small-cell lung cancer by the U.S. FDA last June.

($1 = 0.8350 euros)

(Reporting by Nathan Allen and Aida Pelaez-Fernandez, editing by Andrei Khalip, Inti Landauro and Jane Merriman)